Note: This article is part of a series on risk areas that internal audit teams should consider for their risk assessment and planning for and throughout 2027. Insight-specific articles cover trends in the following areas:
As life sciences organizations prepare for 2027, cybersecurity threats, AI, data privacy concerns, patent expirations, and regulatory changes present interconnected risks to patient safety, operations, revenue, and stakeholder trust.
Internal audit teams should consider prioritizing five areas in internal audit planning for 2027:
By addressing these priorities in their 2027 plans, internal audit teams can help life sciences organizations protect patients, maintain regulatory compliance, and manage risks that could affect long-term performance.
Life sciences companies face growing cybersecurity risk as medical devices, digital health platforms, research systems, manufacturing environments, and sensitive data become more connected. This expanded digital footprint creates additional entry points for attacks across clinical, operational, regulatory, and commercial functions.
Cyberattacks could disrupt patient care, compromise connected devices and treatment platforms, interrupt manufacturing, or expose patient data, clinical trial information, trade secrets, and intellectual property. Potential consequences include patient harm, operational delays, recalls, litigation, regulatory scrutiny, and reputational damage.
The U.S. Food and Drug Administration’s (FDA’s) updated 2026 guidance reinforces the need to manage cybersecurity throughout the life cycle of medical devices. Organizations should strengthen governance, secure design, monitoring, vulnerability management, third-party oversight, incident response, and regulatory compliance.
Major patent expirations and uncertain R&D productivity are increasing pressure on life sciences companies to replace revenue from mature products, and biopharma revenue could be significantly affected by patent expirations through 2027. Longer clinical development timelines could delay replacement products. Negotiated Medicare prices taking effect in 2027 could create additional pressure before some patents expire.
Internal audit should assess whether revenue-replacement plans rely on realistic pipeline, competitive, and commercial assumptions. It should also evaluate whether R&D, licensing, and acquisition decisions use consistent criteria and appropriately balance expected returns against the risk of delays, underperformance, and lost capital.
As organizations expand use of patient, clinical, real-world, biometric, and genomic data across cloud platforms, vendor ecosystems, and AI applications, they are challenged with determining whether privacy governance has kept pace with data reuse, model development, cross-border movement, and secondary commercialization. These data types often carry heightened regulatory expectations, especially health, genetic, biometric, and inferred sensitive data under privacy regimes such as the Health Insurance Portability and Accountability Act (HIPAA), the European Union’s General Data Protection Regulation, and emerging AI rules. The U.S. Department of Health and Human Services also emphasizes minimum necessary use of protected health information under HIPAA, and the National Institute of Standards and Technology’s AI Risk Management Framework highlights the need to manage AI risks to individuals, organizations, and society.
By 2027, the AI risk for life sciences organizations will be less about whether AI is being used and more about whether organizations can demonstrate that its use is governed, controlled, validated, and fit for purpose as it becomes embedded across drug discovery, clinical development, diagnostics, manufacturing, and commercial operations. Biased or unrepresentative data, weak data provenance, inadequate validation, opaque third-party models, and uncontrolled model changes can produce unreliable outputs that misdirect research and development, undermine trial design or evidence, distort diagnostic or manufacturing quality decisions, generate unsupported commercial content, or expose sensitive information. Potential consequences extend from wasted investment and operational rework to regulatory scrutiny, product quality failures, patient harm, and loss of stakeholder trust.
Existing good practice guidelines (GxP) and other applicable obligations still apply when AI is introduced into regulated activities. At the same time, the FDA and the European Medicines Agency’s (EMA’s) January 2026 “Guiding Principles of Good AI Practice in Drug Development” provide an important regulatory signal for AI used across the drug and biological product life cycle by emphasizing a risk-based approach, clear context of use, data governance and documentation, appropriate model development and performance assessment, multidisciplinary expertise, human-centric design, and life cycle management. A September 2026 executive order, “Inaugurating the Era of Super Intelligence,” adds another federal policy signal by directing executive agencies to use super intelligence terminology and to develop potential legislative changes, although it does not itself alter existing regulations, which makes continued monitoring of how the FDA and other agencies implement evolving federal AI policy important for life sciences organizations.
Internal audit can add value by assessing whether management has established a complete, risk-tiered inventory of AI use cases, including embedded vendor functionality and unapproved or shadow AI, with clearly defined contexts of use and accountable business, quality, data, technology, and model owners. For higher-risk applications, audit procedures should move beyond policy review to evidence-based testing of data lineage and use rights, data quality and representativeness, training and test-data separation, validation criteria and performance, subgroup or bias testing where relevant, human oversight, and decision accountability.
Internal auditors should also evaluate whether drift, model and vendor changes, revalidation, incident escalation, corrective and preventive action, rollback or fallback procedures, and retirement are governed throughout the life cycle, and whether third-party contracts and evidence are sufficient to support the organization’s obligations.
Establishing a common control framework that maps these activities to applicable GxP requirements, FDA and EMA principles, and other relevant standards can enable internal audit to establish that AI governance exists and that AI-supported decisions remain traceable, reproducible, monitored, and accountable. These themes are also consistent with ISO/IEC 42001 expectations for defined accountability, data quality and provenance, human oversight, testing, and life cycle controls.
Product quality problems often begin with small control failures, such as unresolved deviations, untraceable results, or insufficiently validated changes. In complex life sciences operations, these issues can affect products, regulatory submissions, and patient safety. Internal audit should identify them early and assess whether they signal broader quality-system weaknesses.
Inspections should test how the quality system works in practice, not simply whether the right procedures exist. Exploratory questions include: “Can the company explain why a deviation occurred?” “Can it show that the CAPA addressed the underlying problem?” “Can it produce complete records quickly and explain differences between sites?” Answers to these questions can reveal whether controls are working.
For medical device manufacturers, the FDA’s Quality Management System Regulation took effect on Feb. 2, 2026. It aligns 21 CFR part 820 with ISO 13485:2016 and introduces an updated inspection process. Internal audit can use this shift as a prompt to test actual practices across sites and jurisdictions.
Technology adds another layer. Digital quality systems, automation, and AI can improve consistency and surface problems sooner, but only when the data and controls behind them can be trusted. A system change, new interface, or algorithm update can alter a validated process without making the impact obvious to users. The FDA’s January 2026 “Guiding Principles for AI in Drug Development” calls for a defined use, proportionate validation, documented data governance, and ongoing monitoring. Internal audit should ask who owns each tool and its output, how it was validated, how changes are approved, and how performance is monitored. Weaknesses here can contribute to warning letters, import alerts, recalls, delayed approvals, or supply disruption, with patient safety as the most serious consequence.